Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and commercializes pharmaceutical, and biotechnology products for human and animal diseases. The company’s products target the treatment of central nervous system (CNS), gastroenterology, pain management and cardiovascular diseases among other indications. The company manufactures products in various dosage forms, including tablets, pellets, capsules, effervescent tablets, and parenteral and cytotoxic formulations such as liquid injections, lyophilized injections and ointments. The company operates in over 85 countries with a network of sales, marketing and distribution operations. It enters into strategic alliances with global pharmaceutical companies for the development and distribution of products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's research and development efforts focus on developing new products and technologies across various therapeutic areas, including oncology, hormones, and novel drug delivery systems (NDDS). The company has filed over 50 patents on novel formulations, API polymorphs/processes, and analytical methods. Intas is actively involved in the development and commercialization of biologics, adhering to European and US regulatory guidelines, and is focused on discovering and developing New Chemical Entities (NCEs) targeting cancer and neurodegenerative diseases. Intas conducts its research and development through its subsidiary, Astron Research, employing over 550 scientists and researchers. Its main areas of focus are developing pharmaceutical formulations and active pharmaceutical ingredients. Its Center of Cell & Gene Therapy (CCGT) is dedicated to developing next-generation gene- and cell-based therapeutics for treating blood-related disorders, blindness, muscular dystrophies, and various cancers. It is equipped with advanced technologies and equipment for cutting-edge research in cell and gene therapy. Plasma Fractionation Center focuses on delivering plasma products to improve the lives of patients with rare bleeding disorders and other ailments. It aims to develop safe, effective, and affordable plasma products using advanced purification technology.